High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: A single centre study

Parikh, P, Powles, R, Treleaven, J, Helenglass, G, Gore, M, Rose, M, Talbot, D, Milan, S, Smith, C, Pinkerton, R, Aboud, H, Cavenagh, J, Rowley, M, McElwain, T and Hewetson, M (1990) High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: A single centre study. British Journal of Cancer, 62 5: 830-833. doi:10.1038/bjc.1990.387


Author Parikh, P
Powles, R
Treleaven, J
Helenglass, G
Gore, M
Rose, M
Talbot, D
Milan, S
Smith, C
Pinkerton, R
Aboud, H
Cavenagh, J
Rowley, M
McElwain, T
Hewetson, M
Title High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: A single centre study
Journal name British Journal of Cancer   Check publisher's open access policy
ISSN 1532-1827
Publication date 1990-01-01
Sub-type Article (original research)
DOI 10.1038/bjc.1990.387
Volume 62
Issue 5
Start page 830
End page 833
Total pages 4
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract In a single centre, 52 newly diagnosed patients with acute myeloid leukaemia (AML) under the age of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and etoposide (Protocol BF11), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered remission using these drugs. An anthracycline was added for those patients not in remission. The overall remission rate (CR) was 86. 5% (45/52), with a minimum follow-up of 90 days. Patients are hospitalised for relatively short periods, and consequentlyrequire less blood product and antibiotic support. Patients in continuing first remission following inauction with Ara-C and etoposide are similar in number to those in continuing first remission who initially received an anthracycline. This would imply that the efficiency of Ara-C and etoposide in inducing long-term disease-free survival is comparable with anthracycline-containing regimens. We conclude that high-dose Ara-C and etoposide used in the first induction cycle for treating AML have good antileukaemic effect with acceptable toxicity.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ResearcherID Downloads
Scopus Import
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 03:55:59 EST by System User